ArticlePharmacoEconomics2015

Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.

Thomas E Delea et al.PubMed ↗Publisher ↗

No numbers read from the abstract.